We used flow cytometry to evaluate post-optimization and the validation of Tim-3/Gal-9 knockdown or overexpression and NLRC4 inflammasome expression in each glioma cell line (Supplementary Figure S8A,B). The gene discussed is NLRC4; the disease is central nervous system cancer.